Dr. Ghosh on Unmet Needs With CAR T-Cell Therapy in DLBCL
Nilanjan Ghosh, MD, PhD, director of the Lymphoma Program and a physician with Levine Cancer Institute, discusses unmet needs with CAR T-cell therapy in diffuse large B-cell lymphoma.
Nilanjan Ghosh, MD, PhD, director of the Lymphoma Program and a physician with Levine Cancer Institute, discusses unmet needs with CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).
CAR T-cell therapy has revolutionized the treatment of many hematologic malignancies, including aggressive B-cell malignancies, like DLBCL. However, despite the intrigue CAR T-cell therapy has garnered in recent years, unmet needs remain, Ghosh says.
Patients with DLBCL who relapse after CAR T-cell therapy generally have poor outcomes, Ghosh explains. In addition, toxicities associated with CAR T-cell therapy, including cytokine release syndrome and neurotoxicity, limit the administration of the therapy to specialized centers.
Future research efforts should focus on mitigating these toxicities to improve the accessibility of CAR T-cell therapy for more patients, Ghosh concludes.
